Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,594.00    28.00 (0.61%)
Bid:
4,592.00
Ask:
4,594.00
Spread: 2.00 (0.044%)
Market Cap: £16.74b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Directorate Change

21 Jun 2017 09:26

RNS Number : 7109I
Coca-Cola HBC AG
21 June 2017
 

FOR IMMEDIATE RELEASE

 

Coca-Cola HBC AG

Composition of the Committees of the Board of Directors of Coca‑Cola HBC AG and determination of a new member of the Board of Directors of Coca‑Cola HBC AG

 

 

Zug, Switzerland - 21 June 2017 - Coca‑Cola HBC AG ("Coca‑Cola HBC" or the "Company") announces today that its board of directors (the "Board") has appointed Ms. Charlotte J. Boyle as a member of the Remuneration Committee, with effect from 20 June 2017.

This appointment has been made pursuant to the announcement released by Coca‑Cola HBC on 15 May 2017 and the election of Ms. Charlotte J. Boyle as a non-executive member of the Board at the Company's annual general meeting held on 20 June 2017, following the retirement of Mr. Antonio D'Amato.

The Board has determined that Ms. Charlotte J. Boyle qualifies as independent under the criteria set forth in the UK Corporate Governance Code.

Aside from the information set out above, no further information is required to be disclosed pursuant to the UK Financial Conduct Authority's Listing Rule 9.6.13 and the new non-executive director does not hold any interests in the shares of Coca‑Cola HBC.

The composition of the Board Committees will be as follows:

Audit Committee

William (Bill) W. Douglas III (Chair)

John P. Sechi

Olusola (Sola) David-Borha

Nomination Committee

Reto Francioni (Chair)

Charlotte J. Boyle

Alexandra Papalexopoulou

Remuneration Committee

Alexandra Papalexopoulou (Chair)

Charlotte J. Boyle

Reto Francioni

Social Responsibility Committee

Anastasios I. Leventis (Chair)

Alexandra Papalexopoulou

José Octavio Reyes

This announcement is made pursuant to Listing Rule 9.6.11.

 

 

 

Enquiries

Coca‑Cola HBC Group

Basak Kotler

Investor Relations Director

Tel: +44 20 37 444 231 basak.kotler@cchellenic.com

Vasso Aliferi

Investor Relations Manager

Tel: +30 210 6183 341

vasso.aliferi@cchellenic.com

Maria Livaniou

Head of Shareowner Service

Tel: +30 210 6183 106

maria.livaniou@cchellenic.com

 

International media contact:

Teneo Blue Rubicon

Rob Morgan

Anushka Mathew

Tel: +44 20 7260 2700 robert.morgan@teneobluerubicon.com anushka.mathew@teneobluerubicon.com

 

Greek media contact:

V+O Communications

Argyro Oikonomou

Tel: +30 211 7501219

 ao@vando.gr

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a leading bottler of The Coca-Cola Company with a sales volume of more than 2 billion unit cases. It has a broad geographic footprint with operations in 28 countries serving a population of approximately 595 million people. Coca-Cola HBC offers a diverse range of non-alcoholic ready to drink beverages in the sparkling, juice, water, sport, energy, tea and coffee categories. Coca-Cola HBC is committed to promoting sustainable development in order to create value for its business and for society. This includes providing products that meet the beverage needs of consumers, fostering an open and inclusive work environment, conducting its business in ways that protect and preserve the environment and contribute to the socio-economic development of the local communities. Coca-Cola HBC is ranked beverage industry leader in the Dow Jones Sustainability World and Europe Indices, and is also included in the FTSE4Good Index.

 

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE: CCH) and its shares are listed on the Athens Exchange (ATHEX: EEE). For more information, please visit http://www.coca-colahellenic.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALIFFTRSILFID
Date   Source Headline
27th Feb 20181:05 pmRNSDirector/PDMR Shareholding
26th Feb 20183:33 pmRNSDirector/PDMR Shareholding
23rd Feb 201810:53 amRNSDirector/PDMR Shareholding
22nd Feb 20184:28 pmRNSHolding(s) in Company
22nd Feb 20183:02 pmRNSDirector/PDMR Shareholding
21st Feb 201810:21 amRNSDirector/PDMR Shareholding
21st Feb 201810:13 amRNSDirector/PDMR Shareholding
20th Feb 20182:16 pmRNSDirector/PDMR Shareholding
20th Feb 20181:31 pmRNSDirector/PDMR Shareholding
20th Feb 20181:19 pmRNSDirector/PDMR Shareholding
20th Feb 20181:00 pmRNSDirector/PDMR Shareholding
16th Feb 201811:22 amRNSDirector/PDMR Shareholding
14th Feb 20187:00 amRNSEXCEPTIONAL SET OF RESULTS
1st Feb 201810:35 amRNSIssue of equity and total voting rights
19th Jan 20184:02 pmRNSDirector/PDMR Shareholding
17th Jan 201811:05 amRNSNotice of Results
5th Jan 20184:02 pmRNSAthens Exchange trading date of ordinary shares
2nd Jan 201810:04 amRNSIssue of equity and total voting rights
20th Dec 20172:15 pmRNSDirector/PDMR Shareholding
7th Dec 20177:00 amRNSAppointment of Chief Executive Officer
1st Dec 20179:06 amRNSIssue of Equity and Total Voting Rights
20th Nov 201711:57 amRNSDirector/PDMR Shareholding
9th Nov 20177:00 amRNSCONTINUING TO DELIVER EXCELLENT REVENUE GROWTH
1st Nov 20179:07 amRNSIssue of Equity and Total Voting Rights
1st Nov 20178:55 amRNSBlock listing Interim Review
18th Oct 201712:55 pmRNSDirector/PDMR Shareholding
9th Oct 201711:45 amRNSNotice of Results
3rd Oct 20177:00 amRNSStatement re. Chief Executive Officer
2nd Oct 20179:27 amRNSIssue of Equity and Total Voting Rights
27th Sep 201711:13 amRNSDirector Declaration
19th Sep 20173:30 pmRNSDirector/PDMR Shareholding
15th Sep 20177:01 amRNSCEO's medical leave of absence
1st Sep 20179:30 amRNSIssue of Equity and Total Voting Rights
21st Aug 201711:37 amRNSDirector/PDMR Shareholding
10th Aug 20177:00 amRNSEXCELLENT FIRST HALF RESULTS
1st Aug 20179:35 amRNSIssue of Equity and Total Voting Rights
28th Jul 20171:02 pmRNSDirector/PDMR Shareholding
19th Jul 20171:51 pmRNSDirector/PDMR Shareholding
4th Jul 201712:56 pmRNSNotice of Results
3rd Jul 20178:16 amRNSIssue of Equity and Total Voting Rights
21st Jun 20179:26 amRNSDirectorate Change
21st Jun 20179:15 amRNSResult of AGM
20th Jun 20173:00 pmRNSDirector/PDMR Shareholding
2nd Jun 201711:42 amRNSAthens Exchange trading date of ordinary shares
1st Jun 20177:54 amRNSIssue of Equity and Total Voting Rights
19th May 201712:24 pmRNSDirector/PDMR Shareholding
16th May 20177:11 amRNSNotice of AGM
15th May 20177:23 amRNSchange to the Board and confirms dividend dates
11th May 20177:00 amRNSYEAR STARTS WELL WITH GOOD REVENUE GROWTH
2nd May 20179:07 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.